Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06942442 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
A Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS), sponsored by Sarcoma Alliance for Research through Collaboration.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 2
- Study locations
NCT06942442: Recruiting Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS), sponsored by Sarcoma Alliance for Research through Collaboration.
NCT06942442 is a Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS) that is actively recruiting participants, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06942442, a Phase 2 study of HLA-A*0201 Positive Cells Present and Clear Cell Sarcoma (CCS), is actively recruiting participants, sponsored by Sarcoma Alliance for Research through Collaboration.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
Primary Outcome
To estimate the population of HLA-A\*02:01-positive patients with metastatic or unresectable clear cell sarcoma and treated with tebentafusp who are progression free at 24 weeks. PFS (progression-free survival) will be determined using iRECIST.
Conditions Studied
Interventions
- DRUG Tebentafusp
- DRUG Physician's Choice
Study Locations (2)
California
- University of Southern California - Norris Cancer Center - Los Angeles
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2030-10-01 |
| Phase | Phase 2 |
What NCT06942442 shows while recruiting
NCT06942442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with HLA-A*0201 Positive Cells Present appearing as the primary indexed condition, and to 2 interventions - of which Tebentafusp is the first listed.
NCT06942442 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT06942442 about?
NCT06942442 is a clinical study titled "A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma". This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
What is the current status of trial NCT06942442?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2025-10-22. Estimated completion is 2030-10-01.
What conditions does trial NCT06942442 study?
This clinical trial studies the following conditions: HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS).
What interventions are being tested in trial NCT06942442?
The interventions under investigation include: Tebentafusp (DRUG), Physician's Choice (DRUG).
Who is sponsoring clinical trial NCT06942442?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06942442 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HLA-A*0201 Positive Cells Present
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06942442's enrollment target sits among peer trials
47 1283rd of 2000 higher than 716 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI